RDUS רווח נקי למניה ב-12 החודשים האחרונים radiuspharm.com
The 12-month earnings per share history for Radius Recycling, Inc. (RDUS) demonstrates stability, where the value of -3.60 expresses the metric level. Raw material supply for the clinic is secured through flexible delivery routes. The leadership of the drug Tymlos and innovative patches guarantee patient adherence in the US. Consequently, the biopharmaceutical ecosystem, supported by protected patents and B2B contracts, firmly maintains its market position.
%20%D7%A8%D7%95%D7%95%D7%97%20%D7%9C%D7%9E%D7%A0%D7%99%D7%94%20%D7%91%D7%90%D7%A8%D7%91%D7%A2%D7%AA%20%D7%94%D7%A8%D7%91%D7%A2%D7%95%D7%A0%D7%99%D7%9D%20%D7%94%D7%90%D7%97%D7%A8%D7%95%D7%A0%D7%99%D7%9D&width=1200&height=400&colorIndex=0&v=mwhdatcg.m7-7dqbc3k&start=20220704&end=20261115&filename=GURU_Markets_-_RDUS_-_Radius-Recycling-Inc._-_Earnings-per-share-for-the-last-four-quarters "Radius Health - רווח נקי למניה (EPS TTM) RDUS (תקופה 04.07.2022 - 26.07.2025) | 👁️GURU.Markets👁️")
פילוחים אנליטיים ודוחות נתונים של חברת Radius Pharmaceuticals (RDUS)
Annual net earnings per share determine the portion of actual income attributable to a single security. Investors utilize this metric to assess real business efficiency and forecast capital growth rates. By analyzing the current EPS value over the last 12 months, one can determine the issuer's ability to generate profit amid volatility. Positive momentum confirms the resilience of Radius Recycling, Inc. (RDUS) as a major secondary raw materials operator. Stable industrial demand for metal provides the company with consistent turnover and fundamental revenue support.
